Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease.

Remo Panaccione MD (Co-Chair)1, Richard N Fedorak MD (Co-Chair)2, Guy Aumais MD3, Charles N Bernstein MD4, Alain Bitton MD5, Ken Croitoru MD6, Robert Enns MD7, Brian Feagan MD8, Marty Fishman MD7*, Gordon Greenberg MD9, Anne Griffiths MD9, John K Marshall MD6*, Imran Rasul MD10*, Daniel Sadowski MD2*, Ernest Seidman MD11, Hillary Steinhart MD9, Lloyd Sutherland MD1, Eric Walli MD12*, Gary Wild MD5, C Noel Williams MD2, Mary Zachos MD9

[1]  R S Wallis,et al.  Granulomatous infectious diseases associated with tumor necrosis factor antagonists. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  P. Rutgeerts,et al.  Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.

[3]  P. Rutgeerts,et al.  Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. , 2004, Gastroenterology.

[4]  Kimberly M. Persley.  Infliximab infusion reactions: desensitizing ourselves to the danger. , 2004, Inflammatory bowel diseases.

[5]  S. Targan,et al.  Infliximab in the treatment of medically refractory indeterminate colitis , 2003, Alimentary pharmacology & therapeutics.

[6]  S. Anker,et al.  Tumour necrosis factor-α and the failing heart , 2003, Basic Research in Cardiology.

[7]  P. Lionetti,et al.  Response to infliximab is related to disease duration in paediatric Crohn's disease , 2003, Alimentary pharmacology & therapeutics.

[8]  M. Regueiro,et al.  Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease , 2003, American Journal of Gastroenterology.

[9]  E. Chung,et al.  Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial , 2003, Circulation.

[10]  J. Satsangi,et al.  An analysis of factors influencing short‐term and sustained response to infliximab treatment for Crohn's disease , 2003, Alimentary pharmacology & therapeutics.

[11]  G. Lichtenstein,et al.  Maintenance infliximab therapy in patients with Crohn's disease: how long, how much, how frequent? , 2003, Gastroenterology.

[12]  S. Plevy,et al.  The Incidence and Management of Infusion Reactions to Infliximab: A Large Center Experience , 2003, American Journal of Gastroenterology.

[13]  M. Braun,et al.  Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist , 2003, Annals of Internal Medicine.

[14]  J. Hugot,et al.  A Prospective Study of the Efficacy and Tolerance of a Chimeric Antibody to Tumor Necrosis Factors (Remicade) in Severe Pediatric Crohn Disease , 2003, Journal of pediatric gastroenterology and nutrition.

[15]  R. Caprilli,et al.  Infliximab in refractory pouchitis complicated by fistulae following ileo‐anal pouch for ulcerative colitis , 2003, Alimentary pharmacology & therapeutics.

[16]  E. Cabré,et al.  Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNFα antibodies (infliximab) , 2003, European journal of gastroenterology & hepatology.

[17]  W. Sandborn.  Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize. , 2003, Gastroenterology.

[18]  M. Peppercorn,et al.  Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. , 2003, Gastroenterology.

[19]  R. Baldassano,et al.  Infliximab (REMICADE) Therapy in the Treatment of Pediatric Crohn's Disease , 2003, American Journal of Gastroenterology.

[20]  M. Regueiro,et al.  Treatment of Perianal Fistulizing Crohn's Disease with Infliximab Alone or as an Adjunct to Exam Under Anesthesia with Seton Placement , 2003, Inflammatory bowel diseases.

[21]  E. Lundorf,et al.  Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease , 2003, Alimentary pharmacology & therapeutics.

[22]  R. Kozarek,et al.  Immunomodulators and “On Demand” Therapy with Infliximab in Crohn's Disease: Clinical Experience with 400 Infusions , 2003, American Journal of Gastroenterology.

[23]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[24]  M. Kamm,et al.  Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging , 2003, Alimentary pharmacology & therapeutics.

[25]  G. Marchal,et al.  Magnetic Resonance Imaging of the Effects of Infliximab on Perianal Fistulizing Crohn's Disease , 2003, American Journal of Gastroenterology.

[26]  R. Baldassano,et al.  Safety and Steroid-Sparing Experience Using Infliximab for Crohn's Disease at a Pediatric Inflammatory Bowel Disease Center , 2003, American Journal of Gastroenterology.

[27]  W. Crandall,et al.  Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model , 2003, Alimentary pharmacology & therapeutics.

[28]  J. Raftery,et al.  Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease. , 2003, Health technology assessment.

[29]  S. Hanauer,et al.  Infliximab in the treatment of Crohn's disease: a user's guide for clinicians , 2002, American Journal of Gastroenterology.

[30]  A. Losco,et al.  Drug side‐effects in IBD , 2002, Alimentary pharmacology & therapeutics.

[31]  J. Mayberry,et al.  Infliximab and Crohn's QOL , 2002, Alimentary pharmacology & therapeutics.

[32]  J. Achkar,et al.  Predictors of response to infliximab in patients with Crohn's disease. , 2002, Gastroenterology.

[33]  Antonio López-Vázquez,et al.  High serum tumor necrosis factor-α levels are associated with lack of response to infliximab in fistulizing Crohn's disease , 2002, American Journal of Gastroenterology.

[34]  G. Porro,et al.  Infliximab in treatment of Crohn's disease: the Milan experience. , 2002, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[35]  R. Modigliani,et al.  An open‐label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease , 2002, Alimentary pharmacology & therapeutics.

[36]  S. Kugathasan,et al.  Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction , 2002, American Journal of Gastroenterology.

[37]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[38]  W. Tremaine,et al.  Management of Internal Fistulas in Crohn's Disease , 2002, Inflammatory bowel diseases.

[39]  C. Sample,et al.  Clinical experience with infliximab for Crohn's disease: the first 100 patients in Edmonton, Alberta. , 2002, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[40]  H. Steinhart,et al.  Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease. , 2004, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[41]  P. Nos,et al.  Hidradenitis Suppurativa and Crohn's Disease: Response to Treatment with Infliximab , 2001, Inflammatory bowel diseases.

[42]  S. Ghosh,et al.  Clinical use of Infliximab in Crohn’s disease: the Edinburgh experience , 2001, Alimentary pharmacology & therapeutics.

[43]  J. Udall,et al.  Use of Infliximab in Pediatric Patients with Inflammatory Bowel Disease , 2001, The Annals of pharmacotherapy.

[44]  R. Cattell,et al.  Infliximab treatment for Crohn's disease , 2001, Postgraduate medical journal.

[45]  R. Panaccione.  Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada. , 2001, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[46]  P. Rutgeerts,et al.  Infliximab induces potent anti‐inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease , 2001, Alimentary pharmacology & therapeutics.

[47]  S. Kugathasan,et al.  Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. , 2001, Inflammatory bowel diseases.

[48]  W. Sandborn,et al.  Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients , 2000, American Journal of Gastroenterology.

[49]  W. Selby,et al.  Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group. , 2001, Internal medicine journal.

[50]  S. Hanauer,et al.  Infliximab in Crohn's disease: first anniversary clinical experience , 2000, American Journal of Gastroenterology.

[51]  Samir A. Shah,et al.  Clinical experience with infliximab therapy in 100 patients with Crohn's disease , 2000, American Journal of Gastroenterology.

[52]  S. Kugathasan,et al.  Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease , 2000, American Journal of Gastroenterology.

[53]  S. Nikolaus,et al.  Mechanisms in failure of infliximab for Crohn's disease , 2000, The Lancet.

[54]  J. Markowitz,et al.  A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. , 2000, Gastroenterology.

[55]  J. Hyams.  Use of Infliximab in the Treatment of Crohn's Disease in Children and Adolescents , 2000, The Journal of pediatrics.

[56]  J. Marshall.  A critical approach to clinical practice guidelines. , 2000, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[57]  M. Kamm,et al.  Infliximab for the treatment of fistulas in patients with Crohn'S disease. , 1999, Gastroenterology.

[58]  E. Vasiliauskas,et al.  Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. , 1999, Gastroenterology.

[59]  W. Sandborn,et al.  Successful management of Crohn's disease of the ileoanal pouch with infliximab. , 1999, Gastroenterology.

[60]  S. Targan,et al.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. , 1997, The New England journal of medicine.